Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Tivozanib As Maintenance Therapy In GYN

This study has been terminated.
(due to slow accrual)
National Comprehensive Cancer Network
AVEO Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Susana M. Campos, MD, Dana-Farber Cancer Institute Identifier:
First received: October 24, 2013
Last updated: August 10, 2016
Last verified: August 2016

This research study is evaluating a drug called tivozanib as a possible treatment for ovarian, fallopian tube or primary peritoneal cancer.

Angiogenesis is the formation of new blood vessels. Tumors need blood vessels to grow and spread. Tivozanib is an anti-angiogenesis medicine that fights cancer by cutting off a tumor's blood supply so that it does not get the blood and nutrients it needs to grow.

In this research study, the Investigators are looking to see whether tivozanib works as a maintenance therapy for ovarian, fallopian tube or primary peritoneal carcinoma in participants who have achieved a complete response following chemotherapy. Maintenance therapy is given after a disease has responded to previous treatment. It is given to help prevent the spread or recurrence of the tumor.

Condition Intervention Phase
Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Carcinoma
Drug: Tivozanib
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study of Tivozanib as Maintenance Therapy, Post-Chemotherapy, in Patients With Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Resource links provided by NLM:

Further study details as provided by Dana-Farber Cancer Institute:

Primary Outcome Measures:
  • Progression-Free Survival (PFS) Comparison [ Time Frame: 2 Years ]

    To compare progression-free survival of maintenance therapy with Tivozanib against standard of care in patients with ovarian, fallopian tube or primary peritoneal carcinoma who have achieved a complete response following therapy for platinum sensitive disease.

    Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1)

Secondary Outcome Measures:
  • Progression-Free Survival (PFS) Evaluation [ Time Frame: 2 Years ]
    To evaluate progression-free survival with no maintenance therapy in patients who have achieved a complete response following therapy for platinum sensitive disease.

  • Overall Survival (OS) Evaluation [ Time Frame: 2 Years ]
    To evaluate the overall survival with and without maintenance therapy with Tivozanib in patients who have achieved a complete response following therapy for platinum sensitive disease.

  • Toxicity Rate Comparison [ Time Frame: 2 Years ]
    To compare rates of toxicity with and without maintenance therapy with Tivozanib.

  • Quality of Life (QOL) Evaluation [ Time Frame: 2 Years ]
    To evaluate the impact of treatment with Tivozanib versus placebo alone on the Quality of Life (QOL) through the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and the EORTC QLQ-Ovarian Cancer Module (EORTC QLQ-OV28) for functioning and symptoms.

Enrollment: 4
Study Start Date: November 2013
Study Completion Date: January 2016
Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Tivozanib
Tivozanib hydrochloride will be administered orally, at a dose of 1.5 mg/day, beginning on Day 1 of Cycle 1. Subjects will receive tivozanib hydrochloride once daily for 3 weeks followed by 1 week off treatment. One cycle is defined as 4 weeks. Cycles will be repeated every 4 weeks in the absence of disease progression or unacceptable toxicities.
Drug: Tivozanib
Other Names:
  • Tivozanib hydrochloride
  • AV-951
No Intervention: Standard Care
Participants in the non-interventional arm will not receive study treatment, and will receive standard clinical observation and study assessments. Patients will continue to be observed in the absence of disease progression or unacceptable toxicities.

Detailed Description:

Once the participant has signed the consent form, they will be asked to undergo some screening tests or procedures to find out if the participant can be in the research study. Many of these tests and procedures are likely to be part of regular cancer care and may be done even if it turns out that the participant do not take part in the research study. If the participant has had some of these tests or procedures recently, they may or may not have to be repeated.

  • A medical history, which includes questions about the participant's health, current medications, and any allergies.
  • Performance status, which evaluates how the participant is able to carry on with their usual activities.
  • A tumor assessment by CT (Computerized Tomography) scan or MRI (Magnetic Resonance Imaging.
  • Blood tests.
  • Urine test.
  • Electrocardiogram (ECG)

If these tests show that the participant is eligible to participate in the research study, the participant will begin the study treatment. If the participant does not meet the eligibility criteria, the participant will not be able to participate in this research study.

Additional research procedures to be performed during this study:

- Archival tumor testing: During this study, additional tests will be performed on a sample of the participant's original tumor that has been stored in the institution's tissue banks. These tests will be performed on tumor tissue samples from previous biopsies or surgeries for the participant's cancer.

The research done on these samples will involve looking at DNA and proteins in the participant's cancer to see if researchers can learn more about the participant's type of cancer and understand how tivozanib might work on their tumor. Testing of this sample will not require the participant to undergo any additional research procedures.

This research sample collection is a required part of this research study.

Tissue collection / Ownership: Participation in this protocol involves providing specimen(s) of participant's tissue. Please know that if the investigator leaves the institution, the research and the tissue might remain at the DF/HCC or might be transferred to another institution.

After the screening procedures confirm that the participant are eligible to participate in the research study:

If the participant takes part in this research study, the participant will be randomized to receive tivozanib by mouth or no therapy. The participant will be given a study drug diary for each treatment if the participant is randomized to the tivozanib group.

Each treatment cycle lasts 28 days (4 weeks). For participants who are randomized to receive tivozanib, the participant will be taking the study drug once per day for 3 weeks followed by a week of rest. The diary will also include special instructions for taking the study drug. The study drug will be taken once a day with plenty of water.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • No evidence of disease on CT/MRI following treatment for recurrent ovarian, fallopian tube, or peritoneal cancer.
  • High-grade papillary serous carcinoma of the ovary, fallopian tube or peritoneum. Histological confirmation of the original primary tumor is required.
  • CA-125 within normal range.
  • Age greater than or equal to 18 years.
  • 1 prior line of therapy (cytotoxic therapy only) in the recurrent setting is allowed. Bevacizumab in the upfront setting allowed, however Bevacizumab or other VEGF pathway targeted therapy in the recurrent setting is not allowed. Hormonal therapy does not count as a prior line.
  • Recovered from effects of recent surgery, radiotherapy, and chemotherapy.
  • ECOG performance status ≤ 2

Organ and marrow function as defined below:

  • Absolute neutrophil count ≥1,250/mcL
  • Platelets ≥100,000/mcL
  • Bilirubin ≤ 1.5 x ULN
  • AST (SGOT) / ALT (SGPT) ≤ 2.5 x institutional upper limit of normal Alkaline phosphatase ≤ to 2.5 x ULN
  • Creatinine ≤ 1.5 x institutional upper limit
  • Less than or equal to 1+ proteinuria on two consecutive dipsticks taken no less than 1 week apart, or < 1 gm protein on 24-hour urine collection or a urine protein:creatinine ratio of < 1.
  • INR < 1.5; if on anticoagulation: INR is required to be between 2 and 3.

Patient must receive one of these three regimens for their platinum sensitive disease (number of cycles should not have exceeded 8 cycles of 1 regimen in the recurrent setting):

  • Platinum (Carboplatin or Cisplatin) and Taxane (Paclitaxel or Docetaxel) Carboplatin and Gemcitabine
  • Carboplatin and Liposomal Doxorubicin
  • Females not of childbearing potential or has documentation of a negative pregnancy test prior to the start of the study treatment are eligible. Sexually active pre-menopausal female subjects must agree to use adequate, highly effective contraceptive measures, while on study and for 45 days after the last dose of last study drug. Effective birth control includes (a) intrauterine device (IUD) plus one barrier method; (b) oral, implantable or injectable contraceptives plus one barrier method; or (c) 2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm).
  • Able and willing to sign a written informed consent document.

Exclusion Criteria:

  • Prior therapy with bevacizumab or other VEGF pathway targeted therapy in the recurrent setting. Bevacizumab in the upfront setting is allowed.
  • Receiving any other study agents.
  • Subjects with treated limited stage basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the breast or cervix are eligible. Subjects with prior cancer treated with a curative intent with no evidence of recurrent disease 5 years following diagnosis and judged by the investigator to be at low risk of recurrence are eligible. Subjects with any other concomitant or prior malignancies are ineligible.
  • Serious non-healing wounds or ulcers at the time of registration.
  • History of abdominal fistula or gastrointestinal perforation.
  • Active bleeding.
  • Clinically significant cardiovascular disease.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to Tivozanib.
  • Symptomatic left ventricular dysfunction or baseline left ventricular ejection fraction (LVEF) by multigated acquisition scan (MUGA) or echocardiogram (ECHO) ≤ 50 % lower limit of institutional normal (LLN).
  • Uncontrolled hypertension: systolic blood pressure of >140 mmHg or diastolic blood pressure of >90 mmHg documented on 2 consecutive measurements taken at least 24 hours apart.
  • Myocardial infarction, severe angina, or unstable angina within 6 months prior to administration of first dose of study drug.
  • History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation).
  • Cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial fibrillation that is well controlled with anti-arrhythmic medication).
  • Coronary or peripheral artery bypass graft within 6 months of screening.
  • History of Class III or IV congestive heart failure, as defined by the New York Heart Association.
  • Central nervous system metastases.

Note: Subjects with previously treated (radiotherapy or surgery) brain metastasis that have been stable without steroid treatment for at least 3 months following prior treatment may be enrolled.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01972516

United States, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Sponsors and Collaborators
Dana-Farber Cancer Institute
National Comprehensive Cancer Network
AVEO Pharmaceuticals, Inc.
Principal Investigator: Susana Campos, MD, MPH Dana-Farber Cancer Institute
  More Information

Responsible Party: Susana M. Campos, MD, Principal Investigator, Dana-Farber Cancer Institute Identifier: NCT01972516     History of Changes
Other Study ID Numbers: 13-375
Study First Received: October 24, 2013
Results First Received: June 13, 2016
Last Updated: August 10, 2016

Keywords provided by Dana-Farber Cancer Institute:
Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer
High-grade Serous

Additional relevant MeSH terms:
Ovarian Neoplasms
Fallopian Tube Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Fallopian Tube Diseases processed this record on May 25, 2017